Aller au contenu principal
Profil bibliographique

Ming Zheng

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

5Publications signalées
15Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Acute Myeloid Leukemia ResearchChronic Lymphocytic Leukemia ResearchRenal Transplantation Outcomes and TreatmentsChronic Myeloid Leukemia TreatmentsHIV/AIDS drug development and treatment

Les publications récentes

Accès ouvert 2026 article OpenAlex

The Effect of Efavirenz and Rufinamide on the Pharmacokinetics and Safety of Quizartinib: Two Phase 1 Studies in Healthy Participants

YoungJun Yoo, Hamim Zahir, Shinichi Inaba, Kyoin Koo et autres

ABSTRACT Quizartinib is an oral, potent, selective FMS‐like tyrosine kinase 3 (FLT3) inhibitor, approved for the treatment of FLT3 ‐internal tandem duplication (ITD)–positive acute myeloid leukemia (AML) and under investigation in patients with newly diagnosed FLT3 ‐ITD–negative AML. Quizartinib is metabolized by …

us, jp (code pays fourni par la source)

0 citations Clinical and Translational Science
Accès ouvert 2024 article OpenAlex

Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3 ‐internal‐tandem‐duplication‐positive acute myeloid leukemia

Pavan K. Vaddady, Anaïs Glatard, Giovanni Smania, Shintaro Nakayama et autres

Abstract The population pharmacokinetics (PK) of quizartinib and its pharmacologically active metabolite AC886 have been previously described in healthy volunteers (HV) and relapsed/refractory (R/R) FLT3‐internal‐tandem‐duplication‐positive (FLT3‐IDT‐positive) acute myeloid leukemia (AML) patients receiving quizartinib monotherapy. In this analysis, we characterized the population PK …

us, jp (code pays fourni par la source)

3 citations Clinical and Translational Science
Accès ouvert 2024 article OpenAlex

Concentration‐ QTcF analysis of quizartinib in patients with newly diagnosed FLT3 ‐internal‐tandem‐duplication‐positive acute myeloid leukemia

Pavan K. Vaddady, Giovanni Smania, Shintaro Nakayama, Hiroyuki Inoue et autres

Abstract Quizartinib prolongs QT interval through inhibition of the slow delayed rectifier potassium current (IKs). We used non‐linear mixed‐effects modeling to explore the relationship between quizartinib and its pharmacologically active metabolite AC886 and the Fridericia‐corrected QT interval (QTcF) in newly diagnosed acute …

us, jp (code pays fourni par la source)

4 citations Clinical and Translational Science
2023 article OpenAlex

Influence of SLCO1B1 Polymorphisms on the Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients

Jiawen Liu, Ruoyun Tan, Min Geun Gu, Zijie Wang et autres

Aims: This study was designed to analyze the correlation between single nucleotide polymorphisms (SNP) related to drug metabolism and pharmacokinetics of mycophenolic acid (MPA) during long-term follow-up. Materials and Method: A retrospective cohort study involving 71 renal transplant recipients was designed. Blood …

cn (code pays fourni par la source)

6 citations Current Drug Metabolism
Accès ouvert 2022 erratum OpenAlex

Author Correction: BTLA suppress acute rejection via regulating TCR downstream signals and cytokines production in kidney transplantation and prolonged allografts survival

Jiayi Zhang, Hengcheng Zhang, Zijie Wang, Haiwei Yang et autres

The correct Figure 3 and accompanying legend appears below. Figure 3 Expression of BTLA in rat allografts in the Allo + NC and Allo + BTLA groups. ( A ) IHC staining showed significantly upregulated BTLA expression in the kidney tissue of …

cn (code pays fourni par la source)

2 citations Scientific Reports

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.